Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis with a high drug interruption rate during the COVID-19 pandemic: a post hoc analysis from a single center of a phase III trial - Shangshang Wang; Zhenghua Zhang; Ling Han; Kexiang Yan; Jinhua Xu (Naunyn-Schmiedeberg's Archives of Pharmacology, 2026)